Neuroplast B.V.

Neuroplast B. V. is a biotechnology company specializing in innovative therapies for neurodegenerative conditions, leveraging its Neuro-Cells® platform to promote healing and regeneration using autologous stem cell technology. Founded in 2014, Neuroplast B.

V. is based in Geleen, Netherlands, and focuses on developing treatments for neurodegenerative conditions. The company has secured investment from Brightlands Venture Partners, Industriebank LIOF, and Lumana Invest, raising a total of EUR 4. 000 mn.

The latest funding round occurred on November 17, 2021, when the company raised EUR 4. 000 mn to support its initiatives. The CEO, Johannes de Munter, leads the team in advancing the company's innovative medical solutions. Neuroplast's primary offering revolves around its innovative Neuro-Cells® platform, which represents a pioneering approach in autologous stem cell therapy.

This therapy is designed to address neurodegenerative conditions resulting from trauma, disease, and aging, specifically targeting injuries such as traumatic brain injury and spinal cord injury, as well as chronic conditions like Alzheimer’s and Parkinson’s diseases. The Neuro-Cells® technology utilizes the patient’s own cells to promote healing and regeneration in the nervous system, thereby providing personalized medical solutions. Neuroplast aims to serve a customer base that includes healthcare providers, research institutions, and potentially direct consumers seeking advanced treatment options for neurodegenerative impairments. Currently, the company is focused on expanding its market reach across Europe and North America, aligning with regions that demonstrate a high prevalence of the targeted conditions.

Neuroplast's revenue model is structured around the provision of its Neuro-Cells® therapy, which involves direct transactions with healthcare providers and potentially participating in partnerships with medical institutions. The company engages in B2B transactions, supplying its innovative stem cell therapy to hospitals and specialized clinics that treat neurodegenerative conditions. The pricing structure is typically based on the complexity of the treatment and the required therapeutic protocols, with each therapy session tailored to the individual needs of the patient. Given the proprietary nature of Neuro-Cells®, the company capitalizes on its unique positioning in the regenerative medicine market, establishing a revenue stream that is influenced by treatment demand and the efficacy of its solutions in clinical settings.

Neuroplast B. V. plans to utilize the EUR 4. 000 mn raised in its most recent funding round to advance towards conditional EMA market approval for its TSCI therapy.

This includes conducting Phase II and III trials, consulting with the EMA, and executing a Health Technology Assessment. Additionally, the company is targeting expansion into new markets, particularly across Europe and North America, where there is a significant prevalence of neurodegenerative conditions. The anticipated growth trajectory aligns with their commitment to advancing treatment options for affected patients.